Publication Overview
The Division of Cardiothoracic Surgery has 62 publications in 2022 as of July.
| SECTION | PUBLICATIONS (2022) |
| Adult Cardiac | 31 |
| Pediatric | 10 |
| Thoracic | 15 |
| Translational | 6 |
Sample of publications:
Adult Cardiac
- Nakashima T, Ogata S, Noguchi T, Nishimura K, Hsu CH, Sefa N, Haas NL, Bĕlohlávek J, Pellegrino V, Tonna JE, Haft J, Neumar RW.Resuscitation. 2022 Jul 3;177:43-51. doi: 10.1016/j.resuscitation.2022.06.022. Online ahead of print.PMID: 35788020
- Sadeh B, Ugolini S, Pinzon OW, Potapov EV, Selzman CH, Bader F, Zuckermann AO, Gomez-Mesa JE, Shah KS, Alharethi R, Morejon-Barragan P, Hanff T, Goldraich LA, Farrero M, MacDonald PS, Drakos S, Mehra MR, Stehlik J.Clin Transplant. 2022 Jul;36(7):e14733. doi: 10.1111/ctr.14733. Epub 2022 Jun 8.PMID: 35652422
- Owyang CG, Donnat C, Brodie D, Gershengorn HB, Hua M, Qadir N, Tonna JE.Artif Organs. 2022 Jul;46(7):1369-1381. doi: 10.1111/aor.14193. Epub 2022 Feb 11.PMID: 35122290
- Pereira SJ.J Card Surg. 2022 Jun;37(6):1671-1673. doi: 10.1111/jocs.16399. Epub 2022 Mar 14.PMID: 35288984
Pediatric
- Robertson DM, Boucek DM, Martin MH, Gray RG, Griffiths ER, Eckhauser AW, Ou Z, Lambert LM, Williams RV, Husain SA.Am J Cardiol. 2022 Jun 9:S0002-9149(22)00532-X. doi: 10.1016/j.amjcard.2022.04.056. Online ahead of print.PMID: 35691707
- Eckhauser AW.J Am Coll Cardiol. 2022 Mar 29;79(12):1181-1182. doi: 10.1016/j.jacc.2022.01.024.PMID: 35331413
- Hobbs RD, Eckhauser AW.J Thorac Cardiovasc Surg. 2022 Feb 19:S0022-5223(22)00208-2. doi: 10.1016/j.jtcvs.2022.02.023. Online ahead of print.PMID: 35260281
Thoracic
- Mitzman B.Semin Thorac Cardiovasc Surg. 2022 Jun 30:S1043-0679(22)00148-4. doi: 10.1053/j.semtcvs.2022.06.016. Online ahead of print.PMID: 35781041 No abstract available.
- Mitzman B, Wang X, Haaland B, Varghese TK Jr.J Surg Oncol. 2022 May 23. doi: 10.1002/jso.26923. Online ahead of print.PMID: 35603987
- Elfaki LA, Luc JGY, Antonoff MB, Cooke DT, Arora RC, Stamp N, Varghese TK Jr, Ouzounian M.JTCVS Open. 2022 May 13. doi: 10.1016/j.xjon.2022.05.005. Online ahead of print.PMID: 35664693
- Brajcich BC, Stigall K, Walsh DS, Varghese TK, Barber AE, Kralovich KA, Wescott AB, Pockaj BA, Ko CY, Laronga C.J Am Coll Surg. 2022 Mar 1;234(3):384-394. doi: 10.1097/XCS.0000000000000055.PMID: 35213503
Translational Science
- Ishidoya Y, Kwan E, Dosdall DJ, Macleod RS, Navaravong L, Steinberg BA, Jared Bunch T, Ranjan R.J Cardiovasc Electrophysiol. 2022 Jul;33(7):1460-1471. doi: 10.1111/jce.15554. Epub 2022 Jun 3.PMID: 35644036
- Ishidoya Y, Kwan E, Dosdall DJ, Macleod RS, Navaravong L, Steinberg BA, Bunch TJ, Ranjan R.J Cardiovasc Electrophysiol. 2022 Jul;33(7):1450-1459. doi: 10.1111/jce.15553. Epub 2022 Jun 7.PMID: 35606341
- Javan H, Li L, Schaaf CL, Lee YS, Salama ME, Dinarello CA, Selzman CH.Ann Thorac Surg. 2022 Jul;114(1):98-107. doi: 10.1016/j.athoracsur.2021.07.044. Epub 2021 Aug 19.PMID: 34419440
- Shah AR, Khan MS, Lange M, Hirahara AM, Stoddard G, Ranjan R, Dosdall DJ.Cardiovasc Eng Technol. 2022 Jun;13(3):452-465. doi: 10.1007/s13239-021-00593-0. Epub 2021 Nov 23.PMID: 34816378
A full list of our research publications from the past couple of years can be found here.
Submitted Funding
Adult Cardio
- Craig Selzman, MD
- Title: Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)
- Sponsor: BioCardia, Inc
- Joseph Tonna, MD
- Title: ECMO Trial- R01
- Sponsor: DHHS National Institutes of Health
- Jason Glotzbach, MD
- Title: K08 Resub
- Sponsor: DHHS National Institutes of Health
Translational Science
- Aromolara Ademuyiwa, PhD
- Title(s): R01 PA 20-185 Targeting IL-6; Role for Leukorienes
- Sponsor: DHHS National Institutes of Health
Study Highlight
PI: Craig Selzman, MD
- Project: A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban.
- Background: There is an unmet clinical need for an alternative to warfarin, such as a direct oral anticoagulant (DOAC), as anticoagulation in patients with an aortic mechanical prosthetic valve. The primary objective is to determine if apixaban is superior to warfarin (INR 2.0-3.0) for patients with an On-X mechanical heart valve for the primary outcome of valve thrombosis and valve-related thromboembolism.
- Study Design: Participants are eligible if they are at least 18 years of age, at least 3 months out from an On-X aortic valve implantation, and currently managing their anticoagulation with warfarin. If enrolled, they will be followed for 2 years. Participants will be randomized to either continue warfarin or switch to apixaban.
Participants randomized to apixaban will receive 5 mg twice daily (BID), or apixaban 2.5 mg BID in participants with 2 or 3 of the following characteristics:
• age ≥ 80 years
• weight ≤ 60 kilograms
• creatinine ≥ 1.5 mg/dL (133 micromol/L)
For participants randomized to apixaban, INR testing will be performed on the current warfarin dose with the following algorithm to initiate apixaban:
1. INR < 2; stop warfarin and start apixaban
2. INR 2.0 to 3.0; hold warfarin for 2 days, start apixaban on day 3
3. INR > 3.0 to 4.0; hold warfarin for 4 days, start apixaban on day 5
4. INR > 4.0; hold warfarin for 2 days, recheck INR, refer to steps 1, 2, or 3
For more information:
- Contact the study coordinator Chloe Skidmore
- NCT: 04142658
Don’t see your publication or research highlight? Want to share new updates or projects in the works?
Please contact Margaret Carlson